BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9388905)

  • 1. [Community trial for safety and immunogenicity of oral-administered lyophilized rBS-WC cholera vaccine].
    Chen Q; Yu S; Wang Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 1996 Nov; 30(6):330-3. PubMed ID: 9388905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
    Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
    Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of mass oral cholera vaccination in Beira, Mozambique.
    Lucas ME; Deen JL; von Seidlein L; Wang XY; Ampuero J; Puri M; Ali M; Ansaruzzaman M; Amos J; Macuamule A; Cavailler P; Guerin PJ; Mahoudeau C; Kahozi-Sangwa P; Chaignat CL; Barreto A; Songane FF; Clemens JD
    N Engl J Med; 2005 Feb; 352(8):757-67. PubMed ID: 15728808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
    Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
    Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults.
    Valera R; García HM; Jidy MD; Mirabal M; Armesto MI; Fando R; García L; Fernández R; Año G; Cedré B; Ramírez M; Bravo L; Serrano T; Palma S; González D; Miralles F; Medina V; Nuñez F; Plasencia Y; Martínez JC; Mandarioti A; Lugones J; Rodríguez BL; Moreno A; González D; Baro M; Solis RL; Sierra G; Barbera R; Domínguez F; Gutiérrez C; Kouri G; Campa C; Menéndez J
    Vaccine; 2009 Nov; 27(47):6564-9. PubMed ID: 19720365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response.
    Mahalanabis D; Ramamurthy T; Nair GB; Ghosh A; Shaikh S; Sen B; Thungapathra M; Ghosh RK; Pazhani GP; Nandy RK; Jana S; Bhattacharya SK
    Vaccine; 2009 Jul; 27(35):4850-6. PubMed ID: 19523608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of travellers' diarrhoea by WC/rBS oral cholera vaccine in young, high-risk travellers.
    Torrell JM; Aumatell CM; Ramos SM; Mestre LG; Salas CM
    Vaccine; 2009 Jun; 27(30):4074-7. PubMed ID: 19376179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral vaccines for cholera control.
    Chaturvedi S; Chaturvedi S
    Natl Med J India; 1997; 10(1):17-8. PubMed ID: 9069701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of intestinal flora after oral vaccination with inactivated whole-cell/recombinant B subunit O139 cholera vaccine.
    Wu HX; Chen Q; Li JD; Huang XF
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Feb; 24(2):220-2, 225. PubMed ID: 14965834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
    Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman SS; Cryz S; Kaper JB
    Rev Med Chil; 1993 Aug; 121(8):857-63. PubMed ID: 8296092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial.
    Kanungo S; Paisley A; Lopez AL; Bhattacharya M; Manna B; Kim DR; Han SH; Attridge S; Carbis R; Rao R; Holmgren J; Clemens JD; Sur D
    Vaccine; 2009 Nov; 27(49):6887-93. PubMed ID: 19761838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of safety and effects on the oral whole cell/recombinant B subunit cholera vaccine in university students and workers].
    Shi NM; Luo FJ; Li SM; Bai YH; Qu Y; Song X
    Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(3):192-5. PubMed ID: 20356556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community-based assessment of safety and immunogenicity of the whole cell plus recombinant B subunit (WC/rBS) oral cholera vaccine in Peru.
    Begue RE; Castellares G; Ruiz R; Hayashi KE; Sanchez JL; Gotuzzo E; Oberst RB; Taylor DN; Svennerholm AM
    Vaccine; 1995 May; 13(7):691-4. PubMed ID: 7668039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.
    Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM
    Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh.
    Qadri F; Chowdhury MI; Faruque SM; Salam MA; Ahmed T; Begum YA; Saha A; Alam MS; Zaman K; Seidlein LV; Park E; Killeen KP; Mekalanos JJ; Clemens JD; Sack DA;
    J Infect Dis; 2005 Aug; 192(4):573-9. PubMed ID: 16028125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation in tablets of a cholera whole cells inactivated vaccine candidate.
    Talavera A; Año G; Pino Y; Castaño J; Uribarri E; Riverón L; Gil S; Fernández S; Cedré B; Valmaseda T; Pérez JL; Infante JF; García L; Sierra G
    Vaccine; 2006 Apr; 24(16):3381-7. PubMed ID: 16460846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of cholera and rise of novel mucosal vaccine.
    Yamamoto T
    Jpn J Infect Dis; 2000 Oct; 53(5):181-8. PubMed ID: 11135702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.